Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Know Your Investor (June Edition): Google Ventures
Know Your Investor (June Edition): Google Ventures
Shots: Google Ventures is an investment arm of Alphabet Inc. That invests profusely in seed-stage companies ranging from software and internet to healthcare, life sciences, and artificial intelligence among others Ever since 2016, GV pivoted to focusing on established companies. The company manages assets worth $10B and 400 active portfolio companies spanning across North America…
June 13, 2024
Disease of the Month – Fabry Disease
Shots:  Fabry disease is a rare inherited neurological disorder that affects the body's ability to break down lipids into smaller components  In this reprise of our Disease of the Month report, we bring an illuminating account of Fabry Disease with deep dive analysis of epidemiology, market size, disease management, available therapies, patient advocacy groups, and…
June 12, 2024
Insights+ Key Biosimilars Events of May 2024
Insights+ Key Biosimilars Events of May 2024
Shots:    Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency     Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients     During May, Teva & Alvotech launched Simlandi injection Treat Multiple Indications. Our…
June 4, 2024
New Drug Designations - April 2024
New Drug Designations – April 2024
Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the FDA, NMPA and EMA. This month’s report includes designations allotted to 11 small molecules, 7 biologics, 7 cell & gene therapies, 1 antiviral, 1 peptide and 3 devices   Lisata Therapeutics’ LSTA1 received ODD this month and was granted with…
May 30, 2024
Know Your Investor (May Edition) Alexandria Venture Investment
Know Your Investor (May Edition): Alexandria Venture Investment
Shots: In the May Edition of the Know Your Investor series, we are focussing on Alexandria Venture Investments, an integral part of Alexandria Real Estate Equities In 2023, Alexandria Venture Investments invested in 24 companies; 5, 8, 5 & 6 every quarter across 2023 respectively For a detailed report on all the investments, reach out…
May 28, 2024
Insights+ EMA Marketing Authorization of New Drugs in April 2024
Insights+: EMA Marketing Authorization of New Drugs in April 2024
Shots:   The EC approved 10 New Chemical Entities in April 2024, leading to treatments for patients and advances in the healthcare industry   In April 2024, the major highlighted drugs were Takeda’s Fruzaqla to treat Adults with mCRC and Johnson & Johnson’s Rybrevant for the treatment NSCLC  PharmaShots has compiled a list of 5 drugs that have received positive…
May 21, 2024
Disease of the Month – Sjögren’s Syndrome
Disease of the Month – Sjögren’s Syndrome
Shots:  A rare autoimmune condition, Sjögren’s Syndrome is characterized by dry mouth and eye. The condition affects 0.5 to 1% of the global population of which 90% of patients are women  In this reprise of our Disease of the Month report, we bring an illuminating account of Sjögren’s Syndrome with deep dive analysis of epidemiology, market size, disease management, available therapies, patient…
May 16, 2024
Insights+ The US FDA New Drug Approvals in April 2024
Insights+: The US FDA New Drug Approvals in April 2024
Shots:   PharmaShots has compiled a list of US FDA-approved drugs in the month of April 2024   The US FDA approved a total of 12 new drugs including 11 new molecular entities and 1 biologic leading to the treatments for patients and advances in the healthcare industry     The major highlighted drug was X4 Pharmaceuticals’ Xolremdi for…
May 14, 2024
Insights+ Key Biosimilars Events of April 2024
Insights+ Key Biosimilars Events of April 2024
Shots:    Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency     Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients     During April, Samsung Bioepis and Sandoz received the EC’s Marketing Authorization approval for Pyzchiva.…
May 2, 2024
Load more